KEYTRUDA monotherapy now approved as neoadjuvant treatment, continued as adjuvant treatment combined with radiotherapy with or without concomitant cisplatin then as monotherapy Based on results of ...
Approval introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 (CPS ≥1) The ...
The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co Inc.’s (NYSE:MRK) Keytruda (pembrolizumab) for adult patients with resectable locally advanced head and neck squamous cell ...
HONG KONG, Jan. 13, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium ...
Keytruda and Efti combination therapy achieved a median overall survival of 17.6 months in head and neck squamous cell carcinoma with PD-L1 CPS less than one. The combination therapy demonstrated a ...
The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology to include ...
An FDA advisory committee will consider whether PD-L1 expression cutoffs should guide use of checkpoint inhibitors to treat advanced gastroesophageal cancers. Current approved indications for three ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results